Lipid Metabolism — MCQs

A 28-year-old man presents with elevated cholesterol levels of 325 mg/dL on routine checkup. His father died of a heart attack at age 42 and had markedly elevated cholesterol throughout his life. The patient's physician initiated lovastatin therapy, resulting in cholesterol levels dropping to 170 mg/dL. The likely cause of the elevated cholesterol in this patient is a mutation in which protein?

Q215Easy

Prostaglandins are:

Q216Easy

What is the typical dyslipidemia pattern associated with diabetes concerning HDL?

Q217Medium

Which of the following fatty acids has the maximum hypocholesterolemic effect?

Q218Easy

Beta-oxidation cycle generates which of the following?

Q219Easy

Which of the following is NOT a component or intermediate of the HMG CoA reductase pathway?

Q220Easy

Pathognomonic enlarged, grayish yellow or orange tonsils are seen in which of the following conditions?

Lipid Metabolism Indian Medical PG Practice Questions and MCQs

Question 211: Which of the following is NOT a lysosomal storage disorder?

A. I cell disease
B. Hunter's disease
C. McArdle's disease (Correct Answer)
D. Farber's disease

Explanation: **Explanation:** The correct answer is **McArdle’s disease** because it is a **Glycogen Storage Disorder (GSD Type V)**, not a lysosomal storage disorder. It is caused by a deficiency of **muscle glycogen phosphorylase (myophosphorylase)**, an enzyme located in the cytosol, not the lysosome. This leads to an inability to break down muscle glycogen during exercise, resulting in exercise intolerance, muscle cramps, and myoglobinuria. **Analysis of other options:** * **I-cell disease (Mucolipidosis II):** A lysosomal disorder caused by a deficiency in **N-acetylglucosaminyl-1-phosphotransferase**. This leads to the failure of tagging enzymes with Mannose-6-Phosphate, causing lysosomal enzymes to be secreted extracellularly rather than being delivered to the lysosome. * **Hunter’s disease (MPS II):** A lysosomal storage disorder (Mucopolysaccharidosis) caused by a deficiency of **Iduronate-2-sulfatase**, leading to the accumulation of heparan and dermatan sulfate. * **Farber’s disease:** A rare lysosomal storage disorder caused by a deficiency of **acid ceramidase**, leading to the accumulation of ceramide in lysosomes. **High-Yield Clinical Pearls for NEET-PG:** * **McArdle’s Hallmark:** "Second wind" phenomenon and a flat lactate curve during an ischemic exercise test. * **Hunter vs. Hurler:** Hunter’s is **X-linked Recessive** and lacks corneal clouding (mnemonic: *"The Hunter needs clear eyes to see the target"*). * **I-Cell Disease:** Characterized by coarse facial features, skeletal abnormalities, and massive amounts of lysosomal enzymes found in the **serum**.

Question 212: Which ketone body is present in the highest concentration in diabetic ketoacidosis?

A. Acetone
B. Pyruvate
C. Acetoacetic acid (Correct Answer)
D. Beta-hydroxybutyrate

Explanation: **Explanation:** The correct answer is **Acetoacetic acid (Option C)**. In the context of standard biochemical definitions and the synthesis pathway, **Acetoacetic acid** is considered the primary ketone body. It is the first ketone body formed in the liver via the HMG-CoA lyase reaction. While Beta-hydroxybutyrate often reaches higher absolute levels in the blood during severe clinical DKA due to the altered redox state (NADH/NAD+ ratio), Acetoacetic acid remains the "parent" ketone body and is the specific molecule detected by the standard **Rothera’s test** and conventional urine dipsticks. **Analysis of Options:** * **A. Acetone:** This is a non-metabolizable byproduct formed by the spontaneous decarboxylation of acetoacetate. It is responsible for the "fruity odor" of the breath but is present in the lowest concentration. * **B. Pyruvate:** This is an intermediate of glycolysis, not a ketone body. In DKA, pyruvate levels do not rise in the same manner as ketone bodies. * **D. Beta-hydroxybutyrate:** While it is technically the most abundant ketone body in the blood during an acute crisis (often in a 3:1 or 10:1 ratio with acetoacetate), it is chemically a hydroxy acid, not a true ketone. Many exams prioritize Acetoacetic acid as the "true" ketone body of highest diagnostic significance in classical biochemistry. **High-Yield Pearls for NEET-PG:** * **Ketogenesis Site:** Occurs exclusively in the **liver mitochondria**. * **Rate-limiting Enzyme:** **HMG-CoA Synthase**. * **Utilization:** Ketone bodies are used by extrahepatic tissues (brain, heart, cortex of kidney) but **not by the liver** due to the absence of the enzyme **Thiophorase** (Succinyl-CoA: acetoacetate CoA transferase). * **Diagnosis:** The Nitroprusside test (Rothera’s) detects Acetoacetate and Acetone, but **not** Beta-hydroxybutyrate.

Question 213: In the mucosal cells, triglycerides are formed primarily in which cellular organelle?

A. Rough endoplasmic reticulum
B. Smooth endoplasmic reticulum
C. Golgi apparatus (Correct Answer)
D. Ribosomes

Explanation: **Explanation:** The synthesis and assembly of **chylomicrons** is a specialized process occurring within the intestinal mucosal cells (enterocytes). While the initial re-esterification of fatty acids and 2-monoacylglycerol into **Triglycerides (TAGs)** begins in the Smooth Endoplasmic Reticulum (SER), the final assembly, maturation, and "packaging" of these triglycerides into nascent chylomicrons—ready for exocytosis—occurs primarily in the **Golgi apparatus**. In the context of NEET-PG, when asked where triglycerides are "formed" or finalized into their transportable lipoprotein form within the mucosa, the **Golgi apparatus** is the definitive site for the final processing and secretory vesicle formation. **Analysis of Options:** * **Rough Endoplasmic Reticulum (RER):** This is the site for protein synthesis. In lipid metabolism, it is responsible for synthesizing **Apolipoprotein B-48**, the essential structural protein for chylomicrons. * **Smooth Endoplasmic Reticulum (SER):** While enzymatic re-synthesis of TAGs occurs here, the SER lacks the machinery for the final packaging and glycosylation required for secretion. * **Ribosomes:** These are solely involved in the translation of mRNA into proteins (like Apo B-48) and do not synthesize lipids. **High-Yield Clinical Pearls for NEET-PG:** * **Apolipoprotein B-48** is unique to chylomicrons and is formed via **RNA editing** of the Apo-B gene (introducing a premature stop codon). * **Abetalipoproteinemia:** A deficiency of Microsomal Triglyceride Transfer Protein (MTP) prevents the loading of TAGs onto Apo B-48, leading to lipid accumulation in enterocytes and malabsorption. * Chylomicrons enter the **lacteals** (lymphatics) first, bypassing the portal circulation, which is why they do not go directly to the liver.

Question 214: A 28-year-old man presents with elevated cholesterol levels of 325 mg/dL on routine checkup. His father died of a heart attack at age 42 and had markedly elevated cholesterol throughout his life. The patient's physician initiated lovastatin therapy, resulting in cholesterol levels dropping to 170 mg/dL. The likely cause of the elevated cholesterol in this patient is a mutation in which protein?

A. Microsomal triglyceride transfer protein
B. LCAT
C. Lipoprotein lipase
D. LDL receptor (Correct Answer)

Explanation: **Explanation:** The clinical presentation describes a classic case of **Familial Hypercholesterolemia (Type IIa Hyperlipoproteinemia)**. The patient has significantly elevated LDL cholesterol and a strong family history of premature coronary artery disease (father’s MI at age 42), which is inherited in an autosomal dominant pattern. **Why the LDL Receptor is correct:** The LDL receptor is responsible for the hepatic uptake of LDL particles from the circulation via apoB-100 recognition. A mutation in this receptor leads to decreased clearance of LDL, resulting in hypercholesterolemia. **Statins (like Lovastatin)** work by inhibiting HMG-CoA reductase, which decreases intracellular cholesterol. This triggers a compensatory **upregulation of LDL receptor expression** on the hepatocyte surface. Since this patient responded well to statins, it indicates he has at least one functional allele (Heterozygous FH) that can be upregulated to clear circulating LDL. **Why other options are incorrect:** * **Microsomal Triglyceride Transfer Protein (MTP):** Deficiency causes Abetalipoproteinemia, characterized by *low* cholesterol and malabsorption, not hypercholesterolemia. * **LCAT (Lecithin-Cholesterol Acyltransferase):** Deficiency leads to Fish-eye disease, characterized by corneal opacities and low HDL, but not isolated high LDL. * **Lipoprotein Lipase (LPL):** Deficiency causes Type I Hyperlipoproteinemia, characterized by massive elevation of *triglycerides* (chylomicronemia) and pancreatitis, rather than isolated high cholesterol. **High-Yield Clinical Pearls for NEET-PG:** * **Type IIa Hyperlipoproteinemia:** Defective LDL receptor or ApoB-100. Presents with Tendon Xanthomas (especially Achilles) and Xanthelasmas. * **Statin Mechanism:** Competitive inhibition of HMG-CoA reductase → ↓ Intracellular cholesterol → ↑ LDL receptor synthesis (upregulation). * **PCSK9 Inhibitors:** A newer class of drugs that prevent LDL receptor degradation, further increasing their density on hepatocytes.

Question 215: Prostaglandins are:

A. Monounsaturated fatty acids
B. Polyunsaturated fatty acids
C. Eicosanoids (Correct Answer)
D. Saturated fatty acids

Explanation: ### Explanation **Correct Answer: C. Eicosanoids** **Why it is correct:** Prostaglandins are a class of physiologically active lipid compounds derived from **Arachidonic acid**, a 20-carbon polyunsaturated fatty acid (PUFA). The term **"Eicosanoid"** is derived from the Greek word *eikosi*, meaning twenty, referring to the 20-carbon structure of these signaling molecules. Eicosanoids include prostaglandins, thromboxanes, leukotrienes, and lipoxins. They function as local hormones (autacoids) that act near their site of synthesis via G-protein coupled receptors. **Why the other options are incorrect:** * **A & D (Mono/Saturated Fatty Acids):** Prostaglandins are not simple fatty acids; they are complex derivatives. Saturated and monounsaturated fatty acids lack the multiple double bonds required to form the cyclic structure characteristic of prostaglandins. * **B (Polyunsaturated fatty acids):** While prostaglandins are *derived* from a PUFA (Arachidonic acid), they are not PUFAs themselves. A PUFA is a long-chain hydrocarbon with multiple double bonds, whereas a prostaglandin contains a specific **cyclopentane ring** and functional groups (like hydroxyl or ketone groups) that define its biological activity. **NEET-PG High-Yield Pearls:** * **Precursor:** The primary precursor for human prostaglandins is **Arachidonic acid (20:4 Δ5,8,11,14)**, which is released from membrane phospholipids by the enzyme **Phospholipase A2**. * **Rate-limiting Enzyme:** **Cyclooxygenase (COX)** is the key enzyme in the cyclic pathway that converts arachidonic acid into Prostaglandin H2 (PGH2). * **Pharmacology Link:** **NSAIDs** (like Aspirin and Ibuprofen) exert their anti-inflammatory and analgesic effects by inhibiting the COX enzymes, thereby reducing prostaglandin synthesis. * **Structural Hallmark:** All prostaglandins contain a **prostanoic acid** skeleton (a 20-carbon fatty acid with a 5-carbon ring).

Question 216: What is the typical dyslipidemia pattern associated with diabetes concerning HDL?

A. Decreased Triglycerides
B. Decreased HDL (Correct Answer)
C. Increased HDL
D. Decreased cholesterol

Explanation: **Explanation:** The characteristic dyslipidemia pattern in Type 2 Diabetes Mellitus (T2DM) is often referred to as the **"Atherogenic Lipid Triad."** This consists of elevated Triglycerides (TG), low HDL-C levels, and the presence of small, dense LDL particles. **Why Decreased HDL is the Correct Answer:** In the insulin-resistant state, there is an increased flux of free fatty acids to the liver, leading to overproduction of VLDL (rich in triglycerides). The enzyme **Cholesteryl Ester Transfer Protein (CETP)** facilitates an exchange where VLDL gives triglycerides to HDL in exchange for cholesteryl esters. This results in **triglyceride-enriched HDL**, which is highly unstable and rapidly cleared from the circulation by **hepatic lipase**. Consequently, the total concentration of circulating HDL particles decreases. **Analysis of Incorrect Options:** * **A. Decreased Triglycerides:** Incorrect. In diabetes, insulin resistance leads to increased lipolysis in adipose tissue and decreased lipoprotein lipase (LPL) activity, resulting in **Hypertriglyceridemia**. * **C. Increased HDL:** Incorrect. As explained above, the increased clearance of TG-rich HDL leads to a significant reduction in HDL levels. * **D. Decreased Cholesterol:** Incorrect. While total cholesterol may vary, the qualitative change involves an increase in pro-atherogenic small dense LDL (sdLDL) and VLDL remnants. **NEET-PG High-Yield Pearls:** * **Key Enzyme:** **Lipoprotein Lipase (LPL)** is insulin-dependent. In diabetes, low LPL activity leads to decreased clearance of VLDL and Chylomicrons. * **Small Dense LDL (Pattern B):** Even if total LDL levels appear normal in a diabetic patient, the particles are smaller and denser, making them more prone to oxidation and atherosclerosis. * **Treatment Goal:** Statins are the first-line therapy, but Fibrates may be added if triglycerides remain severely elevated.

Question 217: Which of the following fatty acids has the maximum hypocholesterolemic effect?

A. Arachidonic acid
B. Linolenic acid (Correct Answer)
C. Linoleic acid
D. Oleic acid

Explanation: ### Explanation The hypocholesterolemic effect of fatty acids refers to their ability to lower plasma cholesterol levels, primarily by increasing the expression of LDL receptors and enhancing the excretion of cholesterol into bile. **Why Linolenic Acid is Correct:** Linolenic acid (specifically **Alpha-Linolenic Acid or ALA**) is an **omega-3 (ω-3)** polyunsaturated fatty acid (PUFA). In the hierarchy of lipid-lowering potential, **omega-3 PUFAs are more potent** than omega-6 PUFAs or monounsaturated fats (MUFAs) in reducing plasma cholesterol and triglyceride levels. They significantly decrease VLDL synthesis in the liver and improve the LDL-to-HDL ratio, making Linolenic acid the most effective among the given choices. **Analysis of Incorrect Options:** * **Linoleic acid (Option C):** This is an **omega-6 (ω-6)** PUFA. While it does lower cholesterol when replacing saturated fats, its hypocholesterolemic effect is quantitatively less potent than that of omega-3 fatty acids like Linolenic acid. * **Arachidonic acid (Option A):** An omega-6 fatty acid derived from linoleic acid. While it is a PUFA, it is primarily a precursor for pro-inflammatory eicosanoids and is not used as a primary dietary intervention for lowering cholesterol. * **Oleic acid (Option D):** This is a **Monounsaturated Fatty Acid (MUFA)** (ω-9). MUFAs are "heart-healthy" but are generally less effective at lowering total plasma cholesterol compared to PUFAs. **High-Yield Clinical Pearls for NEET-PG:** * **Hierarchy of Effect:** Omega-3 PUFA > Omega-6 PUFA > MUFA > Saturated Fatty Acids (which increase cholesterol). * **Essential Fatty Acids:** Linoleic and Linolenic acids are essential because humans lack the enzymes (**Δ12 and Δ15 desaturases**) to introduce double bonds beyond carbon 9. * **P/S Ratio:** A high Polyunsaturated to Saturated fat ratio (P/S ratio) in the diet is clinically recommended to reduce the risk of atherosclerosis. * **Fish Oil:** Rich in EPA and DHA (derivatives of Linolenic acid), fish oil is the most potent dietary source for lowering serum triglycerides.

Question 218: Beta-oxidation cycle generates which of the following?

A. FADH2
B. NADH
C. Both FADH2 and NADH (Correct Answer)
D. Neither FADH2 nor NADH

Explanation: **Explanation:** Beta-oxidation is the primary metabolic pathway for the breakdown of fatty acids in the mitochondrial matrix. Each cycle of beta-oxidation removes a two-carbon unit in the form of **Acetyl-CoA** and involves four sequential reactions: Oxidation, Hydration, Oxidation, and Thiolysis. 1. **Step 1 (Oxidation):** Catalyzed by *Acyl-CoA dehydrogenase*, this step involves the removal of hydrogen atoms, which are transferred to FAD, forming **FADH2**. 2. **Step 3 (Oxidation):** Catalyzed by *3-hydroxyacyl-CoA dehydrogenase*, this step involves another oxidation where NAD+ acts as the electron acceptor, forming **NADH**. Therefore, each turn of the cycle generates **one FADH2 and one NADH**, making Option C the correct answer. **Analysis of Incorrect Options:** * **Option A & B:** These are partially correct but incomplete. Beta-oxidation is a redox process that utilizes both FAD and NAD+ as coenzymes at different enzymatic steps to maximize energy yield. * **Option D:** This is incorrect as the primary purpose of beta-oxidation (besides producing Acetyl-CoA for the TCA cycle) is to generate these reduced coenzymes, which then enter the Electron Transport Chain (ETC) to produce ATP. **High-Yield Clinical Pearls for NEET-PG:** * **Site:** Occurs in the mitochondrial matrix (except for Very Long Chain Fatty Acids, which begin oxidation in **Peroxisomes**). * **Rate-limiting step:** Catalyzed by **Carnitine Palmitoyltransferase-I (CPT-I)**, which is inhibited by Malonyl-CoA. * **Energy Yield:** One FADH2 yields ~1.5 ATP, and one NADH yields ~2.5 ATP. * **Clinical Correlation:** **MCAD deficiency** (Medium-Chain Acyl-CoA Dehydrogenase deficiency) is the most common inborn error of beta-oxidation, presenting with fasting hypoglycemia and non-ketotic dicarboxylic aciduria.

Question 219: Which of the following is NOT a component or intermediate of the HMG CoA reductase pathway?

A. Pyruvate (Correct Answer)
B. Cholesterol
C. Mevalonate
D. Acetyl CoA

Explanation: The **HMG-CoA reductase pathway** (also known as the Mevalonate pathway) is the primary metabolic route for the de novo synthesis of cholesterol in the liver and other tissues. ### **Why Pyruvate is the Correct Answer** **Pyruvate** is a product of glycolysis and a precursor to Acetyl-CoA, but it is **not** a direct intermediate or component of the cholesterol biosynthetic pathway itself. While Pyruvate can be converted into Acetyl-CoA via the Pyruvate Dehydrogenase complex, it exists "upstream" of the specific enzymatic reactions that define the HMG-CoA reductase pathway. ### **Analysis of Other Options** * **Acetyl-CoA (Option D):** This is the starting substrate. Two molecules of Acetyl-CoA condense to form Acetoacetyl-CoA, which then reacts with a third Acetyl-CoA to form HMG-CoA. * **Mevalonate (Option C):** This is the key intermediate formed when HMG-CoA is reduced by the enzyme **HMG-CoA Reductase**. This step is the rate-limiting and committed step of the pathway. * **Cholesterol (Option B):** This is the final end-product of the pathway, synthesized after a series of complex steps involving isoprenoid units, squalene, and lanosterol. ### **NEET-PG High-Yield Pearls** * **Rate-Limiting Enzyme:** HMG-CoA Reductase (located in the ER membrane). * **Pharmacology Link:** **Statins** (e.g., Atorvastatin) are competitive inhibitors of HMG-CoA Reductase. * **Subcellular Location:** The enzymes are located in the **cytosol** and **endoplasmic reticulum**. * **Key Intermediates (Sequence):** Acetyl-CoA → HMG-CoA → **Mevalonate** → Isoprenoid units → Squalene → Lanosterol → Cholesterol. * **Energy Requirement:** The synthesis of one molecule of cholesterol is highly energy-intensive, requiring 18 Acetyl-CoA, 36 ATP, and 16 NADPH.

Question 220: Pathognomonic enlarged, grayish yellow or orange tonsils are seen in which of the following conditions?

A. Familial hypercholesterolemia
B. LCAT deficiency
C. Tangier disease (Correct Answer)
D. Abetalipoproteinemia

Explanation: **Explanation:** **Tangier Disease (Correct Answer):** Tangier disease is an autosomal recessive disorder caused by a mutation in the **ABCA1 gene** (ATP-binding cassette transporter A1). This transporter is essential for the efflux of free cholesterol from cells to lipid-poor Apolipoprotein A-I (ApoA-I) to form nascent HDL. * **Mechanism:** Due to the defect, cholesterol cannot be exported, leading to its accumulation as **cholesteryl esters** within the reticuloendothelial system (macrophages). * **Clinical Presentation:** The hallmark sign is **enlarged, orange-colored tonsils** caused by massive cholesterol deposition. Other features include hepatosplenomegaly, peripheral neuropathy, and extremely low levels of HDL (often <5 mg/dL). **Incorrect Options:** * **Familial Hypercholesterolemia:** Caused by a defect in LDL receptors. It presents with high LDL levels, **tendon xanthomas**, and xanthelasma, but does not involve orange tonsils. * **LCAT Deficiency:** Characterized by the inability to esterify cholesterol in plasma. Key features include **corneal opacities** (fish-eye disease), hemolytic anemia, and renal failure. * **Abetalipoproteinemia:** Caused by a mutation in the **MTP gene**, leading to an absence of ApoB-48 and ApoB-100. It presents with malabsorption, **acanthocytosis** (spur cells), and retinitis pigmentosa. **High-Yield Clinical Pearls for NEET-PG:** * **ABCA1 Mutation:** Think Tangier Disease (Orange Tonsils). * **ApoB-48/100 Deficiency:** Think Abetalipoproteinemia (Acanthocytes). * **LPL or ApoC-II Deficiency:** Think Type I Hyperlipoproteinemia (Eruptive xanthomas, milky plasma). * **HDL Levels:** In Tangier disease, HDL is virtually absent, significantly increasing the risk of premature atherosclerosis.

Practice by Chapter

Lipid Classification and Chemistry

Practice Questions

Fatty Acid Oxidation

Practice Questions

Ketone Body Metabolism

Practice Questions

Fatty Acid Synthesis

Practice Questions

Metabolism of Triacylglycerols

Practice Questions

Phospholipid Metabolism

Practice Questions

Cholesterol Metabolism and Biosynthesis

Practice Questions

Bile Acids and Bile Salts

Practice Questions

Lipoprotein Metabolism and Transport

Practice Questions

Dyslipidemias and Atherosclerosis

Practice Questions

Prostaglandins and Eicosanoids

Practice Questions

Fatty Liver and Lipotropic Factors

Practice Questions

Want unlimited practice?

Get full access to all questions, explanations, and performance tracking.

Start For Free